A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies

References

• Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: aUA guideline. J Urol. 2018;200:633–641. doi: 10.1016/j.juro.2018.05.004.
   PubMed Web of Science ®Google Scholar
• Eardley I. The incidence, prevalence, and natural history of erectile dysfunction. Sex Med Rev. 2013;1(1):3–16. doi:10.1002/smrj.2.
   PubMedGoogle Scholar
• Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the “cologne male survey. Int J Impot Res 2000 [cited 2023 May 24];12:305–311. doi:10.1038/sj.ijir.3900622.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010 [cited 2023 Feb 21];57(5):804–814. doi:10.1016/j.eururo.2010.02.020.
   PubMed Web of Science ®Google Scholar
• Salonia A, Bettocchi C, Boeri L, et al. European association of urology guidelines on sexual and reproductive health—2021 update: male sexual dysfunction[Formula presented]. Eur Urol. 2021;80(3):333–357. doi:10.1016/j.eururo.2021.06.007.
   PubMed Web of Science ®Google Scholar
• Saigal CS, Wessells H, Pace J, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006 [cited 2023 Feb 21];166:207–212. doi:10.1001/archinte.166.2.207.
   PubMed Web of Science ®Google Scholar
• Nik-Ahd F, Shindel AW. Pharmacotherapy for erectile dysfunction in 2021 and beyond. Urologic Clinics of North America. W.B. Saunders; 2022. p. 209–217. doi:10.1016/j.ucl.2021.12.002.
   Google Scholar
• Lue TF, Wood AJJ. Erectile dysfunction. N Engl J Med. 2000;342(24):1802–1813. doi:10.1056/NEJM200006153422407.
   PubMed Web of Science ®Google Scholar
• Mitidieri E, Cirino G, d’Emmanuele di Villa Bianca R, et al. Pharmacology and perspectives in erectile dysfunction in man. Pharmacol Ther. 2020;208:107493. Elsevier Inc. doi:10.1016/j.pharmthera.2020.107493
   PubMed Web of Science ®Google Scholar
• Chen J, Godschalk M, Katz PG, et al. Peyronie’s-like plaque after penile injection of prostaglandin E1. J Urol. 1994 [cited 2023 Feb 21];152(3):961–962. doi:10.1016/S0022-5347(17)32624-1.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13(4):465–488. doi:10.1016/j.jsxm.2016.01.016.
   PubMed Web of Science ®Google Scholar
• Aversa A, Francomano D, Lenzi A. Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?Expert Opin Pharmacother. 2015 [cited 2023 Mar 5];16(5):625–628. doi:10.1517/14656566.2015.1011124.
   PubMed Web of Science ®Google Scholar
• Francis SH, Busch JL, Corbin JD, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010 [cited 2023 Mar 5];62(3):525–563. doi:10.1124/pr.110.002907.
   PubMed Web of Science ®Google Scholar
• Katz EG, Tan RBW, Rittenberg D, et al. Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Ther Clin Risk Manag.
   Web of Science ®Google Scholar
• Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902–912. doi:10.1016/j.eururo.2013.01.012.
   PubMed Web of Science ®Google Scholar
• Sadovsky R, Brock GB, Gutkin SW, et al. Toward a new “EPOCH”: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Clin Pract 2009 [cited 2023 Mar 5];63:1214–1230. doi:10.1111/j.1742-1241.2009.02119.x.
   PubMed Web of Science ®Google Scholar
• Kim SC, Lee YS, Seo KK, et al. Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. Int J Impot Res. 2014 [cited 2023 Mar 5];26(3):87–93. doi:10.1038/ijir.2013.41.
   PubMed Web of Science ®Google Scholar
• Carvalheira AA, Pereira NM, Maroco J, et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J Sex Med. 2012 [cited 2023 Mar 5];9(9):2361–2369. doi:10.1111/j.1743-6109.2012.02787.x.
   PubMed Web of Science ®Google Scholar
• Ljunggren C, Hedelin H, Salomonsson K, et al. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med. 2008 [cited 2023 Mar 5];5(2):469–475. doi:10.1111/j.1743-6109.2007.00688.x.
   PubMed Web of Science ®Google Scholar
• Chen L, Staubli SEL, Schneider MP, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68(4):674–680. doi:10.1016/j.eururo.2015.03.031.
   PubMed Web of Science ®Google Scholar
• Burns PR, Rosen RC, Dunn M, et al. Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily. J Sex Med. 2015 [cited 2023 Apr 16];12(3):720–727. doi:10.1111/jsm.12818.
   PubMed Web of Science ®Google Scholar
• Yafi FA, Sharlip ID, Becher EF. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction.Sex Med Rev. 2018 [cited 2023 Mar 5];6(2):242–252. doi:10.1016/j.sxmr.2017.08.001.
   PubMed Web of Science ®Google Scholar
• Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.Circulation. 2010 [cited 2023 Mar 5];122(1):88–95. doi:10.1161/CIRCULATIONAHA.110.944603.
   PubMed Web of Science ®Google Scholar
• Nehra A, Jackson G, Miner M, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012 [cited 2023 Mar 5];87(8):766–778. doi: 10.1016/j.mayocp.2012.06.015.
   PubMed Web of Science ®Google Scholar
• Hamzehnejadi M, Ranjbar Tavakoli M, Abiri A, et al. A review on phosphodiesterase-5 inhibitors as a topical therapy for erectile dysfunction. Sex Med Rev. 2022;10(3):376–391. doi:10.1016/j.sxmr.2022.02.002.
   PubMed Web of Science ®Google Scholar
• Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002;56(6):453–459. doi:10.1111/j.1742-1241.2002.tb11296.x.
   PubMed Web of Science ®Google Scholar
• Laxman S, Beavo JA. Cyclic nucleotide signaling mechanisms in trypanosomes: possible targets for therapeutic agents.Mol Interv. 2007 [cited 2023 Mar 5];7(4):203–215. doi:10.1124/mi.7.4.7.
   PubMedGoogle Scholar
• Dysfunction Erectile dysfunction: medical treatment - sexual medicine and andrology | urology core curriculum. [cited 2023 Mar 5]. Available from: https://university.auanet.org/core/sexual-medicine-andrology/erectile-dysfunction-medical-treatment/index.cfm.
   Google Scholar
• Rezaee ME, Gross MS. Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors?J Sex Med. 2020 [cited 2023 Mar 5];17(8):1579–1582. doi:10.1016/j.jsxm.2020.05.019.
   PubMed Web of Science ®Google Scholar
• Jeon YH, Heo YS, Kim CM, et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci. 2005 [cited 2023 Apr 13];62(11):1198–1220. doi:10.1007/s00018-005-4533-5.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Moysidis K, Bekos A, et al. Treatment strategy for “non-responders” to tadalafil and vardenafil: a real-life study. Eur Urol. 2006 [cited 2023 Mar 5];50(1):126–133. doi:10.1016/j.eururo.2006.02.060.
   PubMed Web of Science ®Google Scholar
• FDA FDA highlights of prescribing information (VIAGRA). [cited 2023 Mar 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20895s039s042lbl.pdf.
   Google Scholar
• Mathers MJ, Klotz T, Roth S, et al. Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. Andrologia. 2009 [cited 2023 Mar 5];41(3):169–175. doi:10.1111/j.1439-0272.2008.00910.x.
   PubMed Web of Science ®Google Scholar
• Gökçe A, Halis F, Demirtas A, et al. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. BJU Int 2011 [cited 2023 Mar 5];107:1274–1277. doi:10.1111/j.1464-410X.2010.09646.x.
   PubMed Web of Science ®Google Scholar
• Corona G, Razzoli E, Forti G, et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest. 2008 [cited 2023 Mar 5];31(9):799–808. doi:10.1007/BF03349261.
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Seftel AD, Kim ED, et al. Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. J Sex Med. 2013 [cited 2023 Mar 5];10(3):844–856. doi:10.1111/j.1743-6109.2012.02898.x.
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Kim ED, Rosen RC, et al. Response to treatment with tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. Int J Impot Res. 2008 [cited 2023 Mar 5];20(6):554–560. doi:10.1038/ijir.2008.38.
   PubMed Web of Science ®Google Scholar
• Seftel A, Goldfischer E, Kim ED, et al. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol. 2011 [cited 2023 Mar 5];185(1):243–248. doi:10.1016/j.juro.2010.09.035.
   PubMed Web of Science ®Google Scholar
• Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002 [cited 2023 Mar 5];168(4 Part 1):1332–1336. doi:10.1016/S0022-5347(05)64442-4.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, McVary KT, Elion-Mboussa A, et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008 [cited 2023 Mar 5];180(4):1228–1234. doi:10.1016/j.juro.2008.06.079.
   PubMed Web of Science ®Google Scholar
• Goldstein I, McCullough AR, Jones LA, et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. J Sex Med. 2012 [cited 2023 Mar 5];9(4):1122–1133. doi:10.1111/j.1743-6109.2011.02629.x.
   PubMed Web of Science ®Google Scholar
• Boeri L, Capogrosso P, Ventimiglia E, et al. Avanafil - a further step to tailoring patient needs and expectations. Expert Rev Clin Pharmacol. 2016 [cited 2023 Apr 13];9(9):1171–1181. doi:10.1080/17512433.2016.1195261.
   PubMed Web of Science ®Google Scholar
• FDA Highlights of Prescribing Information (STENDRA) [Internet]. [cited 2023 Mar 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202276s000lbl.pdf.
   Google Scholar
• McVary KT, Polepalle S, Riggi S, et al. Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. J Urol 1999 [cited 2023 Mar 5];162:726–730. doi:10.1097/00005392-199909010-00025.
   PubMed Web of Science ®Google Scholar
• Udeoji DU, Phan A, Katsiyiannis P, et al. Topical testosterone gel for the treatment of male hypogonadism. 2012 [cited 2023 Mar 5];4:217–230. doi:10.104137/CMTS7348
   Google Scholar
• Pastorini S, Cocimano V, Pugno E, et al. Topical treatment of erectile dysfunction. possibilities and perspectives. Arch Ital Urol Androl. 1995;67:299–302.
   PubMedGoogle Scholar
• Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) study group. N Engl J Med. 1997 [cited 2023 Mar 5];336(1):1–7. doi:10.1056/NEJM199701023360101.
   PubMed Web of Science ®Google Scholar
• Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE study group. Br J Urol 1998 [cited 2023 Mar 5];81:889–894. doi:10.1046/j.1464-410x.1998.00703.x.
   PubMedGoogle Scholar
• Cai T, Palumbo F, Liguori G, et al. The intra-meatal application of alprostadil cream (vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial. Int J Impot Res. 2019 [cited 2023 Mar 5];31(2):119–125. doi:10.1038/s41443-018-0087-6.
   PubMed Web of Science ®Google Scholar
• Williams G, Abboü CC, Amar ET, et al. The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE study group. Br J Urol 1998 [cited 2023 Mar 5];82:847–854. doi:10.1046/j.1464-410X.1998.00937.x.
   PubMedGoogle Scholar
• Ekman P, Sjögren L, Englund G, et al. Optimizing the therapeutic approach of transurethral alprostadil. BJU Int 2000 [cited 2023 Mar 5];86:68–74. doi:10.1046/j.1464-410x.2000.00723.x.
   PubMed Web of Science ®Google Scholar
• Porst H. Transurethral alprostadil with MUSETM (medicated urethral system for erection) vs intracavernous alprostadil—a comparative study in 103 patients with erectile dysfunction. Int J Impot Res. 1997 [cited 2023 Mar 5];9:187–192. doi: 10.1038/sj.ijir.3900318.
   PubMed Web of Science ®Google Scholar
• Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130–171. doi:10.1111/jsm.12023.
   PubMed Web of Science ®Google Scholar
• Steidle C, Padma-Nathan H, Salem S, et al. Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. Urology. 2002 [cited 2023 Mar 5];60(6):1077–1082. doi:10.1016/S0090-4295(02)01980-5.
   PubMed Web of Science ®Google Scholar
• Rooney M, Pfister W, Mahoney M, et al. Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. J Sex Med. 2009 [cited 2023 Mar 5];6(2):520–534. doi:10.1111/j.1743-6109.2008.01118.x.
   PubMed Web of Science ®Google Scholar
• Moncada I, Cuzin B. Clinical efficacy and safety of vitaros©/virirec© (alprostadil cream) for the treatment of erectile dysfunction.Urologia. 2015 [cited 2023 Mar 5];82(2):84–92. doi:10.5301/uro.5000116.
   PubMedGoogle Scholar
• Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients.Urology. 2006 [cited 2023 Mar 5];68(2):386–391. doi:10.1016/j.urology.2006.02.027.
   PubMed Web of Science ®Google Scholar
• Does alprostadil cream hit the spot? Drug Ther Bull. 2015 [cited 2023 Mar 5];53:21–24. doi: 10.1136/dtb.2015.2.0310
   PubMedGoogle Scholar
• Kattan S, Collins JP, Mohr D. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.Urology. 1991 [cited 2023 Jan 27];37(6):516–518. doi:10.1016/0090-4295(91)80314-W.
   PubMed Web of Science ®Google Scholar
• Adaikan PG, Ratnam SS. Pharmacological consideration of intracavernous drug injection in the treatment of impotence. Acta Urol Belg. 1988;56:149–153.
   PubMedGoogle Scholar
• Belew D, Klaassen Z, Lewis RW. Intracavernosal injection for the diagnosis, evaluation, and treatment of erectile dysfunction: a review. Sex Med Rev. 2015;3(1):11–23. doi:10.1002/smrj.35.
   PubMedGoogle Scholar
• Porst H, Buvat J, Meuleman E, et al. Intracavernous alprostadil alfadex–an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study. Int J Impot Res 1998 [cited 2023 Jan 27];10:225–231. doi:10.1038/sj.ijir.3900365.
   PubMed Web of Science ®Google Scholar
• Seyam R, Mohamed K, Al Akhras A, et al. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1. Int J Impot Res. 2005 [cited 2023 Jan 27];17(4):346–353. doi:10.1038/sj.ijir.3901313.
   PubMed Web of Science ®Google Scholar
• de Meyer JM, Oosterlinck W, Meyer JMD. Influence of the method of intracavernous injection on penile rigidity: a possible pharmacokinetic explanation. Urology. 1997 [cited 2023 Jan 27];49(2):248–252. doi: 10.1016/S0090-4295(96)00435-9
   PubMed Web of Science ®Google Scholar
• Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The alprostadil study group.N Engl J Med. 1996 [cited 2023 Jan 27];334(14):873–877. doi:10.1056/NEJM199604043341401.
   PubMed Web of Science ®Google Scholar
• Moriel EZ, Rajfer J. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol. 1993 [cited 2023 Jan 27];149:1299–1300. doi: 10.1016/S0022-5347(17)36373-5.
   PubMed Web of Science ®Google Scholar
• Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol. 1996;155(3):802–815. doi:10.1016/S0022-5347(01)66315-8.
   PubMed Web of Science ®Google Scholar
• Virag R, Adaikan PG. Effects of prostaglandin E1 on penile erection and erectile failure.J Urol. 1987 [cited 2023 Jan 27];137(5):1010. doi:10.1016/S0022-5347(17)44344-8.
   PubMed Web of Science ®Google Scholar
• El-Sakka AI. Intracavernosal prostaglandin E1 self vs office injection therapy in patients with erectile dysfunction. Int J Impot Res. 2006;18(2):180–185. doi:10.1038/sj.ijir.3901388.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Guazzoni G, Bergamaschi F, et al. Intracavernous vasoactive pharmacotherapy: the impact of a new self-injection device. J Urol. 1993 [cited 2023 Jan 27];150(6):1829–1832. doi:10.1016/S0022-5347(17)35907-4.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Guazzoni G, Bergamaschi F, et al. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence. Acta Diabetol. 1994 [cited 2023 Feb 16];31(1):1–5. doi:10.1007/BF00580752.
   PubMed Web of Science ®Google Scholar
• Virag R. Intracavernous injection of papaverine for erectile failure. Lancet. 1982 [cited 2023 Feb 16];2:938. doi: 10.1016/S0140-6736(82)90910-2.
   PubMed Web of Science ®Google Scholar
• Virag R, Shoukry K, Floresco J, et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol. 1991 [cited 2023 Feb 16];145(2):287–292. doi:10.1016/S0022-5347(17)38316-7.
   PubMed Web of Science ®Google Scholar
• Maggi M, Filippi S, Ledda F, et al. Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol. 2000 [cited 2023 Feb 16];143(2):143–154. doi:10.1530/eje.0.1430143.
   PubMed Web of Science ®Google Scholar
• Domer FR, Wessler G, Brown RL, et al. Involvement of the sympathetic nervous system in the urinary bladder internal sphincter and in penile erection in the anesthetized cat. Invest Urol. 1978;15:404–407.
   PubMedGoogle Scholar
• Bechara A, Casabé A, Chéliz G, et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol. 1997;157(6):2132–2134. doi:10.1016/S0022-5347(01)64694-9
   PubMed Web of Science ®Google Scholar
• Meinhardt W, Lycklama a Nijeholt AAB, Kropman RF, et al. Comparison of a mixture of papaverine, phentolamine and prostaglandin E(1), with other intracavernous injections. Eur Urol. 1994 [cited 2023 Feb 16];26(4):319–321. doi:10.1159/000475407.
   PubMed Web of Science ®Google Scholar
• Coombs PG, Heck M, Guhring P, et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012 [cited 2023 Feb 16];110(11):1787–1791. doi:10.1111/j.1464-410X.2012.11080.x.
   PubMed Web of Science ®Google Scholar
• Bechara A, Casabé A, Chéliz G, et al. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol. 1996;155(3):913–914. doi:10.1016/S0022-5347(01)66344-4.
   PubMed Web of Science ®Google Scholar
• ADAIKAN PG, KARIM SMM, KOTTEGODA SR, et al. Cholinoreceptors in the corpus cavernosum muscle of the human penis. J Auton Pharmacol. 1983 [cited 2023 Feb 16];3(2):107–111. doi:10.1111/j.1474-8673.1983.tb00526.x.
   PubMedGoogle Scholar
• Sogari PR, Telöken C, Souto CAV. Atropine role in the pharmacological erection test: study of 228 patients.J Urol. 1997 [cited 2023 Feb 16];158(5):1760–1763. doi:10.1016/S0022-5347(01)64122-3.
   PubMed Web of Science ®Google Scholar
• KIELY EA, BLOOM SR, WILLIAMS G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.Br J Urol. 1989 [cited 2023 Feb 16];64(2):191–194. doi:10.1111/j.1464-410X.1989.tb05986.x.
   PubMedGoogle Scholar
• Ehmke H, Jünemann KP, Mayer B, et al. Nitric oxide synthase and vasoactive intestinal polypeptide colocalization in neurons innervating the human penile circulation. Int J Impot Res. 1995;7:147–156.
   PubMedGoogle Scholar
• Gerstenberg TC, Metz P, Ottesen B, et al. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol. 1992 [cited 2023 Feb 16];147(5):1277–1279. doi:10.1016/S0022-5347(17)37541-9.
   PubMed Web of Science ®Google Scholar
• Dinsmore WW, Gingell C, Hackett G, et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. BJU Int 1999 [cited 2023 Feb 16];83:274–279. doi:10.1046/j.1464-410x.1999.00935.x.
   PubMed Web of Science ®Google Scholar
• Sandhu D, Curless E, Dean J, et al. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction. Int J Impot Res. 1999 [cited 2023 Feb 16];11(2):91–97. doi:10.1038/sj.ijir.3900388.
   PubMed Web of Science ®Google Scholar
• Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008 [cited 2023 Feb 16];102:933–937. doi: 10.1111/j.1464-410X.2008.07764.x.
   PubMed Web of Science ®Google Scholar
• Mcmahon CG, Samali R, Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy.J Urol. 1999 [cited 2023 Mar 5];162(6):1992–1998. doi:10.1016/S0022-5347(05)68085-8.
   PubMed Web of Science ®Google Scholar
• Nandipati K, Raina R, Agarwal A, et al. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. 2006 [cited 2023 Mar 5];18(5):446–451. doi:10.1038/sj.ijir.3901448.
   PubMed Web of Science ®Google Scholar
• McMahon CG. Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy.Int J Impot Res. 2003 [cited 2023 Mar 5];15(5):383–384. doi:10.1038/sj.ijir.3901046.
   PubMed Web of Science ®Google Scholar
• Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy.Eur Urol. 2000 [cited 2023 Mar 5];38(1):30–34. doi:10.1159/000020248.
   PubMed Web of Science ®Google Scholar
• Nehra A, Blute ML, Barrett DM, et al. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot Res. 2002 [cited 2023 Mar 5];14(Suppl 1):S38–S42. doi: 10.1038/sj.ijir.3900795
   PubMedGoogle Scholar
• Raina R, Nandipati KC, Agarwal A, et al. Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl 2005 [cited 2023 Mar 5];26:757–760. doi:10.2164/jandrol.05035.
   PubMedGoogle Scholar
• Moncada I, Martinez-Salamanca J, Ruiz-Castañe E, et al. Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. Int J Impot Res. 2018;30(5):203–208. doi:10.1038/s41443-018-0046-2.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Oettel M. Testosterone and sleep-related erections: an overview*.J Sex Med. 2005 [cited 2023 Feb 21];2(6):771–784. doi:10.1111/j.1743-6109.2005.00095.x.
   PubMed Web of Science ®Google Scholar
• Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983 [cited 2023 Feb 21];57(3):557–562. doi:10.1210/jcem-57-3-557.
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Eardley I, Giuliano F, et al. EAU guidelines on penile curvature. Eur Urol. 2012 [cited 2023 Feb 21];62(3):543–552. doi:10.1016/j.eururo.2012.05.040.
   PubMed Web of Science ®Google Scholar
• Mónica FZ, Antunes E. Stimulators and activators of soluble guanylate cyclase for urogenital disorders.Nat Rev Urol. 2018 [cited 2023 Mar 5];15(1):42–54. doi:10.1038/nrurol.2017.181.
   PubMed Web of Science ®Google Scholar
• Archer SL. Potassium channels and erectile dysfunction.Vasc Pharmacol. 2002 [cited 2023 Mar 5];38(1):61–71. doi:10.1016/S1537-1891(02)00127-1.
   PubMed Web of Science ®Google Scholar
• Malerba M, D`amato M, Radaeli A, et al. Efficacy of andolast in mild to moderate asthma: a randomized, controlled, double-blind multicenter study (the andast trial). Curr Pharm Des. 2015 [cited 2023 Mar 5];21(26):3835–3843. doi:10.2174/1381612821666150407101614.
   PubMed Web of Science ®Google Scholar
• Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther. 2006 [cited 2023 Mar 5];17(12):1165–1176. doi:10.1089/hum.2006.17.1165.
   PubMed Web of Science ®Google Scholar
• Ralph DJ, Eardley I, Taubel J, et al. Efficacy and safety of MED2005, a topical glyceryl trinitrate formulation, in the treatment of erectile dysfunction: a randomized crossover study. J Sex Med. 2018 [cited 2023 Mar 5];15(2):167–175. doi:10.1016/j.jsxm.2017.12.003.
   PubMed Web of Science ®Google Scholar
• van der Kraan M, Tatro JB, Entwistle ML, et al. Expression of melanocortin receptors and pro-opiomelanocortin in the rat spinal cord in relation to neurotrophic effects of melanocortins. Mol Brain Res. 1999 [cited 2023 Mar 5];63(2):276–286. doi: 10.1016/S0169-328X(98)00291-5
   PubMedGoogle Scholar
• van der Ploeg LHT, Martin WJ, Howard AD, et al. A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci, USA. 2002 [cited 2023 Mar 5];99(17):11381–11386. doi: 10.1073/pnas.172378699
   PubMed Web of Science ®Google Scholar
• Wessells H, Hruby VJ, Hackett J, et al. Ac-nle-c[Asp-his-dPhe-arg-trp-lys]-NH2 induces penile erection via brain and spinal melanocortin receptors. Neuroscience. 2003 [cited 2023 Mar 5];118(3):755–762. doi:10.1016/S0306-4522(02)00866-7.
   PubMed Web of Science ®Google Scholar
• King SH, V MA, Balse-Srinivasan P, et al. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7:1098–1106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17584130
   PubMed Web of Science ®Google Scholar
• Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. Int J Impot Res. 2000 [cited 2023 Mar 5];12(Suppl 4):S74–S79. doi: 10.1038/sj.ijir.3900582
   PubMed Web of Science ®Google Scholar
• Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004 [cited 2023 Mar 5];16(1):51–59. doi:10.1038/sj.ijir.3901139.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to viagra. Int J Impot Res 2004 [cited 2023 Mar 5];16:135–142. doi:10.1038/sj.ijir.3901200.
   PubMed Web of Science ®Google Scholar
• Lansdell MI, Hepworth D, Calabrese A, et al. Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans. J Med Chem. 2010 [cited 2023 Mar 5];53(8):3183–3197. doi:10.1021/jm9017866.
   PubMed Web of Science ®Google Scholar
• Intracavernosal injection of botulinum toxin type a in the treatment of vascular erectile dysfunction - full text view - ClinicalTrials.Gov [Internet]. [cited 2023 Mar 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02584686.
   Google Scholar
• Botulinum toxin for erectile dysfunction - full text view - ClinicalTrials.Gov [Internet]. [cited 2023 Mar 5]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03102762.
   Google Scholar
• Ghanem H, Raheem AA, Fathy I, et al. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sexual Med Rev. 2018 [cited 2023 Mar 5];6(1):135–142. doi:10.1016/j.sxmr.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Patel H, Panchal MS, Shah S. Formulation and evaluation of transdermal gel of sildenafil citrate. Int J Pharm Res Allied Sci. 2012 [cited 2023 Mar 5];1:103–118. Available from www.ijpras.com
   Google Scholar
• Baek JS, Cho CW. Transdermal delivery of tadalafil using a novel formulation. Drug Deliv. 2016 [cited 2023 Mar 5];23:1571–1577. doi: 10.3109/10717544.2015.1077291.
   PubMed Web of Science ®Google Scholar
• Meadows KL, Rushing C, Honeycutt W, et al. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer. 2015 [cited 2023 Mar 5];23(5):1311–1319. doi:10.1007/s00520-014-2465-z.
   PubMed Web of Science ®Google Scholar
• Fernández-Codina A, Kazem M, Pope JE. Possible benefit of tadalafil cream for the treatment of raynaud’s phenomenon and digital ulcers in systemic sclerosis.Clin Rheumatol. 2020 [cited 2023 Mar 5];39(3):963–965. doi:10.1007/s10067-020-04966-z.
   PubMed Web of Science ®Google Scholar
• Patel DP, Pastuszak AW, Hotaling JM. Emerging treatments for erectile dysfunction: a review of novel, non-surgical options. Curr Urol Rep. 2019 [cited 2023 Mar 5];20(8). doi: 10.1007/s11934-019-0908-2
   Web of Science ®Google Scholar
• Kim S, Cho MC, Cho SY, et al. Novel emerging therapies for erectile dysfunction. World J Mens Health. 2021 [cited 2023 Mar 5];39(1):1–17. doi:10.5534/wjmh.200007.
   PubMedGoogle Scholar
• Gingell JC, Lockyer R. Emerging pharmacological therapies for erectile dysfunction.Expert Opin Ther Patents. 2005 [cited 2023 Mar 5];9(12):1689–1696. doi:10.101517/135437769121689.
   Google Scholar
• Shadiack AM, Sharma SD, Earle DC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem 2007 [cited 2023 Mar 5];7:1137–1144. doi:10.2174/156802607780906681.
   PubMed Web of Science ®Google Scholar
• Elnaggar YSR, El-Massik MA, Abdallah OY. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. Int J Nanomedicine. 2011 [cited 2023 Mar 5];6:3195–3205. doi: 10.2147/IJN.S25825.
   PubMed Web of Science ®Google Scholar
• el Maghraby GM, Alanazi FK, Alsarra IA, et al. Transdermal delivery of tadalafil. I. Effect of vehicles on skin permeation. Drug Dev Ind Pharm. 2009 [cited 2023 Mar 5];35:329–336. doi: 10.1080/03639040802360494.
   PubMed Web of Science ®Google Scholar
• Eardley I, Montorsi F, Jackson G, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 2007 [cited 2023 Apr 13];100:122–129. doi:10.1111/j.1464-410X.2007.06916.x.
   PubMed Web of Science ®Google Scholar
• Mykoniatis I, Pyrgidis N, Zilotis F, et al. The effect of combination treatment with low-intensity shockwave therapy and tadalafil on mild and mild-to-moderate erectile dysfunction: a double-blind, randomized, placebo-controlled clinical trial. J Sex Med. 2022 [cited 2023 Jun 1];19(1):106–115. doi:10.1016/j.jsxm.2021.10.007.
   PubMed Web of Science ®Google Scholar